JAK3/BTK-IN-2

• UNSPSC Description:

  JAK3/BTK-IN-2 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)[1]

• Target Antigen:

  Btk; JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jak3-btk-in-2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=CC(N1C[C@H](NC2=C3C(NC=C3C4CC4)=NC(NC5=CN(C6CCOCC6)N=C5)=N2)CCC1)=O

• Molecular Weight:

  476.57

• References & Citations:

  [1]Guobao Zhang, et al. Pyrimidopyrroles. Patent WO2021147952A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2674036-93-0